Greennovation and Erganeo announce the signing of an exclusive license agreement to accelerate the development of electro-membrane processes supporting the ecological transition.
The start-up Lafame and Erganeo announce the signing of an exclusive licensing agreement for an innovative bioinformatics process in virology, aimed at securing the effectiveness of treatments and vaccines.
The start-up uGetWin and Erganeo announce the signing of an exclusive license for the exploitation of technological innovations.
The start-up Octogone Medical and Erganeo signed an exclusive license for a non-invasive stroke risk prediction system. A joint innovation by Octogone Medical, Université Paris Cité, INSERM and AP-HP.
Start-up Pegmatiss Biotech and Erganeo have signed an exclusive licence for the use of an implantable biomaterial that is completely resorbable.
Idylle and Erganeo have concluded a licensing contract to use a new process for achieving transparency in biological samples for tissue imaging.
The company Quality Electrodynamics, King’s College London and Erganeo have signed a licence agreement for the exploitation of a new MRI acquisition method.
EVerZom, a spin-off of CNRS/Université Paris Cité specializing in exosomes, announces the signing of a second exclusive licensing agreement with Erganeo.
The start-up Imisca and Erganeo have signed an exclusive licence for the exploitation of a new gel-forming solution to reduce the recurrence rate after local treatment of colorectal cancer.
After signing a research collaboration agreement with the APHP, start-up Augmented Endoscopy and Erganeo have signed an exclusive license for the exploitation of the Axaro.ai solution.
Erganeo and METHYS Dx announce news of an exclusive licensing agreement for the use of diagnostic biomarkers via liquid biopsy.
An exclusive license was signed on 10 November, 2022, between Erganeo and the start-up Persea, for development of a new treatment for liver cancer.
An antibody enabling the development of new medical tests for the diagnosis of SARS-CoV-2 antibodies and other disease related to serological antibodies.
A co-exclusive license has been signed between Erganeo and companies Polyscope and Cube Biotech for the development and marketing of two versions of polymers that show improved solubilisation efficiencies of membrane proteins.
In March 2022, Erganeo signed a technology license transfer agreement with Emvista, a software company, concerning a linguistic resource: the French Tree Bank.
Erganeo signed a licensing agreement with Northern Irish company Hi Viso Ltd for a new device, the Crawliskate®, a piece of ground-breaking technology that helps newborns crawl.
Erganeo and start-up Evora Biosciences signed a world-exclusive license agreement for a new-generation digestive fistula cellular therapy treatment.
License agreement with an american start-up in the treatment of anaemia and rare genetic disorders.
On Tuesday, 3 December, Erganeo and start-up EVerZom signed an exclusive licensing agreement for the development of an innovative extracellular vesicle bioproduction procedure.
Monday, 17 June 2019, Erganeo and the start-up Orixha signed an exclusive worldwide license for the use of an innovative liquid ventilation technology.
